IFLR1000

Johnson & Johnson $30 billion acquisition of Actelion

26/1/2017
Public acquisition, Demerger
Select tab

$ 30 billion

Announced

26/1/2017

Overview:

  • Johnson & Johnson made a $30 billion tender offer for Swiss pharmaceuticals and biotechnology company Actelion.
  • The deal includes the demerger of a new research and development biotechnology company containing Actelion's drug discovery operations along with the majority of its clinical pipeline.
  • Johnson & Johnson will own an initial 16% in the new company, to be listed on the SIX Swiss Exchange, potentially rising to 32% in the future.

Jon Moore - Journalist

Jurisdiction:

Switzerland

Deal types:

Public acquisition
Demerger

Practice area:

M&A

Governing law:

Switzerland

Industry sector:

Pharmaceuticals and life sciences

Firms:
Cravath Swaine & Moore

Party: Johnson & Johnson (Acquirer)

Lawyer: Robert Townsend III

Homburger

Party: Johnson & Johnson (Acquirer)

Lawyers: Daniel Daeniker, Daniel Haeberli, Daniel Hasler, Eduard De Zordi

Niederer Kraft Frey

Party: Actelion (Target)

Lawyers: Philipp Haas, Ulysses von Salis

Slaughter and May

Party: Actelion (Target)

Lawyer: Simon Nicholls

Wachtell Lipton Rosen & Katz

Party: Actelion (Target)

Lawyers: Daniel Neff, Gregory Ostling

Related deals